This post was originally published on this site
Morgan Stanley, Jefferies, Cowen, and Lifesci Capital are acting as underwriters of the offering. The underwriters a 30-day option to purchase up to an additional 1,635,000 shares of common stock at the IPO price.
Third Harmonic Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development of the next wave of medicine for the treatment of allergic and inflammatory diseases.
